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Purpose: To develop swellable controlled porosity osmotic pump tablet of theophylline and to define the 
formulation and process variables responsible for drug release by applying statistical optimization 
technique.  
Methods: Formulations were prepared based on Taguchi Orthogonal Array design and Fraction 
Factorial design for core and coating, respectively. The tablets were prepared by direct compression 
and wet granulation methods; spray coated with ethyl cellulose solution containing varying amounts of 
PEG 400 and plasdone. Drug release from the osmotic drug delivery system was studied using USP 
Type I paddle type apparatus. The membrane morphology of the delivery system was determined by 
scanning electron microscopy (SEM). 
Results: Optimization results indicated that the release rate of theophylline from the swellable controlled 
porosity osmotic pump tablet is directly proportional to the levels of osmotic agent, solubilizing agent and 
pore former in the tablet core and the membrane, respectively. SEM showed the formation of pores in 
the membrane through which drug release occurred. The best formulation showed 98.2 % drug release 
and complied with USP requirements. 
Conclusion: The results confirmed that the factors responsible for drug release were osmotic agents 
(core) and pore former (membrane). Also, the preparation of swellable controlled porosity osmotic pump 
tablet was facilitated by coating the core tablet with pore forming agent, thus eliminating the need for the 
more expensive laser drilling. 
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INTRODUCTION 
 
In recent years, considerable attention has 
been focused on the development of novel 
drug delivery systems (NDDS)
1
. Once-daily 
controlled release preparation is often 
desirable
2
. However, drug release from oral 
controlled release dosage forms may be 
affected by pH, gastric motility, and presence 
of food. One practical approach with a 
potential to overcome these disadvantages is 
the osmotic drug delivery system where 
osmotic materials have been used 
extensively in the fabrication of drug delivery 
systems
3
. The historical developments of 
osmotic systems include seminal 
contributions such as the Rose-Nelson 
pump
4
, the Higuchi-Leeper pumps
5
, the Alzet 
osmotic pump
6
, the elementary osmotic 
pump (EOP)
7
 and the push-pull osmotic 
pump
8
. The osmotic drug delivery systems 
suitable for oral administration typically 
consist of a compressed tablet core that is 
coated with a semipermeable membrane that 
has an orifice drilled on it by means of a laser 
beam. The rate at which the core absorbs 
water depends on the osmotic pressure 
generated by the core components and the 
permeability of the membrane coating. As the 
core absorbs water, it expands in volume, 
which pushes the drug solution or suspension 
out of the tablet through one or more delivery 
ports
9
. To obviate the need for complicated 
laser drilling, tablets coated with a membrane 
of controlled porosity have been described. 
These membranes consist of a leachable 
material which dissolves upon contact with 
water, leaving behind the pores through 
which the drug solution is pumped out. 
However, due to the relatively low 
permeability of the dense coatings, osmotic 





Asthma is an inflammatory disease 
characterized by bronchial hyper-




Theophylline (THP), which was selected as a 
model poorly soluble drug, has been used in 
asthma and chronic obstructive pulmonary 
disease for over 60 years and remains one of 
the most widely prescribed drugs in the 
treatment of airway diseases worldwide as it 
is inexpensive
12
. THP (1.3-dimethylxanthine) 
is a member of the xanthine family, 
sometimes referred to as purine alkaloid, and 
seems to have the same precursor as the 
nucleic acid
13
. It has a molecular weight of 
180.17 and pKa of 3.5 and 8.6 
14
; it relaxes 
smooth muscles and relieves broncospasm
15
 
by inhibiting the enzyme phosphodiesterase 
which degrades cyclic nucleotides 
intracellularly
16
. Theophylline may be a useful 
treatment for nocturnal asthma and a single 
dose of a slow-release theophylline 
preparation given at night may provide 





In this study, an attempt was made to design 
a simplified new swellable controlled porosity 
osmotic system for the delivery of a poorly 
soluble drug that eliminates the need for 
complicated and expensive laser drilling. This 
device is known as swellable controlled 
porosity osmotic pump (SCPOP). The study 
involves the use of Taguchi Orthogonal Array 
design
18,19
 and fraction factorial design
 18,20 
for 
core and membrane formulation, 
respectively, and was intended to determine 
the effect of different independent variables 
on dependent (response) variables. In these 
systems, the hydrostatic force were produced 
by osmotic agents and polymer swelling force 
concurrently to drive the drug out of the 
system through the pores created by the 
pore-forming agent in the membrane coating 
after exposure of the system to water. In 
order to optimize release rate from the 
osmotic devices, the data from in vitro 
release studies were subjected to analysis of 
variance (ANOVA), and polynomial equations 
were developed to determine the quantitative 
relationship between dependent and 
independent variables by using Design 
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The theophylline (THP) and croscarmellose 
sodium (CCS) were obtained as gifts from 
Microlabs Pvt Ltd, Bangalore, India. Xanthan 
gum, plasdone S630, sodium lauryl sulphate 
(SLS), microcrystalline cellulose (MCC), ethyl 
cellulose, polyethylene glycol 400 (PEG 400), 
tartaric acid, sorbitol and triacetin were also 
obtained as gifts from Strides Arco Labs Pvt 
Ltd, Bangalore, India. All other chemicals 






Taguchi orthogonal array design
18,19
 was 
inculcated to develop formulations as outlined 
in Table 1. It is a large screening design that 
utilizes two-, three-, and mixed-level 




Core tablets of THP were prepared by both 
direct compression and wet granulation. In 
the direct compression method, all the 
ingredients were weighed accurately, as per 
Table 1, screened through a sieve of aperture 
size 250 µm and blended for 5 min using 
double cone blender (Rimek Kalveka HD-410 
AC, Gujarat, India) at 100 rpm to get a 
uniform mix. Magnesium stearate and talc 
were added and blended for 2 min.  
 
In the wet granulation method, the drug was 
mixed with all the excipients except the 
binding and solubilizing agents and passed 
through sieve of aperture size 250 µm. The 
blend was mixed for 5 min using a double 
cone blender (Rimek Kalveka HD-410 AC, 
Gujarat, India.) at 100 rpm. The mixture was 
granulated with a granulating fluid prepared 
by dissolving the binding and 
wetting/solubilising agents in water. The 
resulting wet mass was passed through a 
sieve of aperture size 710 µm and the 
granules were dried at 50 
o
C for 15 min. The 
granules were then screened through a sieve 
of aperture size 355 µm, and blended with 
magnesium stearate and talc.  
 
The granules obtained by both methods were 
compressed at a pressure of 6 tons in a 
laboratory press (Rimek RSB-4, Minipress, 
Gujarat, India) fitted with two sizes of 
concave punch sets - 10 and 12 mm 
diameter, respectively.  
 
Measurement of tablet thickness 
 
The thickness of ten tablet cores per batch 
was measured with electronic digital calipers 
(Aerospace, China) and mean thickness was 
calculated. 
 
Assay of theophylline 
 
The theophylline content of each tablet 
formulation was analyzed spectrophoto-
metrically (Shimadzu UV-1601) at 271 nm 
based on the crushed material from 5 
randomly selected tablets from each batch. 
The tablet material was dissolved in 0.1 M 
HCl and appropriately diluted with the same 
medium to yield a concentration that falls in 
the Beer’s range of 2 – 16 µg/ml. The drug 
content was calculated using the formula in 
Eq 1. 
X = Y - 0.019/0.0558   …………………  (1) 
where X = concentration (µg/ml) and  
Y = absorbance. 
 
Coating of tablets 
 
Coating formulations were designed based 
on fraction factorial design. This design 
reduces the number of experiments required, 
compared with Factorial Design (FD), 
especially when the numbers of factors are 
high. The higher and lower levels of 
independent variables selected are described 
in Table 2. Dependent variables selected for 
the study include % drug release at 24 h. 
Core formulation F1 was selected to optimize 
the coating formula.  
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Table 1: Taguchi orthogonal array design for core tablet formulations* 
 
Ingredient (mg) F1 F2 F3 F4 F5 F6 F7 F8 
Plasdone 30 30 5 30 5 5 5 30 
CCS 5 5 50 50 5 5 50 50 
Xanthum gum 10 25 25 25 25 10 10 10 
Potassium chloride 300 300 300 150 150 150 300 150 
Tartaric acid 100 50 50 100 100 50 100 50 
SLS 2.5 12.5 2.5 2.5 12.5 2.5 12.5 12.5 
Total (mg) 572.5 547.5 557.5 482.5 422.5 347.5 602.5 427.5 
*Compositions are given in terms of mg per tablet. Each formulation contained 100 mg, 10 mg, 10 mg, and 5 mg of 
theophylline, MCC, magnesium stearate and talc, respectively. (CCS = crosscarmellose sodium; SLS = sodium lauryl 
sulphate, MCC = microcrystalline cellulose) 
   
 
                      Table 2: Fraction factorial design for 12 coating formulations* 
 




Sorbitol (g) Plasdone 
(g) 
C1 0.707 - 1.2 - 
C2 - 0.173 1.2 - 
C3 0.353 - - 1.2 
C4 0.707 - 0.6 - 
C5 0.707 - - 0.6 
C6 - 0.519 - 0. 
C7 - 0.173 0.6 - 
C8 0.353 - - 0.6 
C9 - 0.519 1.2 - 
C10 0.353 - 0.6 - 











C12 - 0.173 - 1.2 
      
            *Each formulation contained 2 g and 100 ml of ethyl cellulose and ethanol, respectively. 
 
 
A coating solution (2% w/v) of ethyl cellulose 
in ethyl alcohol (containing varying amounts 
of plasticizer and pore forming agent) was 
used to apply a semi permeable film on the 
tablets. The coating was carried out by 
spraying in a coating pan (Rimek Kalveka 
HD-410 AC, Gujarat, India) equipped with a 
hot air blower. The stainless steel pan was 
set a rotating speed of 25 rpm and a spray 
rate of 5 ml/min. The coated tablets were 
dried at 50 
o
C for 4 h. 
 
In vitro release studies 
 
In vitro drug release of the formulations was 
carried out in a USP dissolution apparatus 
(paddle type) set at a rotating speed of 100 
rpm and temperature of 37±1 
o
C. The 
dissolution medium (900 ml) was Simulated 
Gastric Fluid (SGF IP 2007, pH 1.2) for the 
first 2 h and Simulated Intestinal Fluid (SIF IP 
2007, pH
 
6.8) thereafter. Samples (4 ml) were 
withdrawn at specified time intervals over a 
24 h period and the medium was replenished 
with fresh dissolution fluid. The samples were 
suitably diluted, analyzed spectrophoto-
metrically at 271 nm and drug release 
computed.  
 
Measurement of film thickness  
 
Following the completion of dissolution, the 
film was isolated from the tablets and dried at 
40 
o
C for 1 hr. Thickness was measured at 
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three different points on the film using 
electronic digital calipers (Aerospace, China.) 




The response values (24 h drug release) of 
coating formulations based on Fraction 
Factorial Design were subjected to analysis 
by response surface reduced quadratic 
model. The optimized coating formula was 
used to coat the 8 batches of tablets 
formulated according to Taguchi orthogonal 
array design. Core optimization was carried 
out based on Factorial model for 1, 4, 8, and 
24 h drug release.  
 
Scanning electron microscopy 
 
The surface morphology of the optimized 
tablet film coating before and after dissolution 
was examined by scanning electron 
microscope. The samples were fixed on a 
brass stub using double-sided tape and then 
gold-coated in vacuum by a sputter coater. 
Scans were taken at an excitation voltage of 
20 KV in a JSM-840A scanning electron 
microscope fitted with JFC-1100E ion 




Tablet thickness and drug content   
 
The thickness of tablet formulations F1 – F8 
(10 mm diameter) and the optimized core 
tablet formulation (12 mm diameter) was in 
the range 3.87 – 5.92 mm for the former and 
5.2 mm for the latter. Thickness depended on 
punch size and tablet weight; coefficient of 
variation (based on 20 tablets/batch) for each 
batch was less than ± 5 %, which indicates 
good thickness uniformity. Drug content was 
uniform within each batch and ranged from 




The optimized coating formula in Table 3 
obtained after optimization showed a weight 
gain of 2% w/w, compared with the uncoated 
tablet. Film thickness of 0.065 mm and 
maximum in vitro release of 94.12 % were 
observed.  
 
Table 3: Composition of optimized formula-




    Ethylcellulose 2 g 
    Ethanol 100 ml 
    PEG 400 0.674 ml 
    Plasdone 1.10 g 
  
Core (tablet) per tablet (mg) 
    Theophylline 100 
    Plasdone 29.91 
    CCS 12.98 
    Xanthan gum 24.17 
    KCl 299.99 
    Tartaric acid 99.91 
    SLS 12.49 
    Microcrystalline cellulose 10 
    Mg stearate 10 





First, the coating formulation was optimized 
using Response Surface Reduced quadratic 
model based on core formulation F1. 
 
Influence of coating formulation variables 
on drug release 
 
The response values for percentage drug 
release at 24 h in the design run formulations 
were subjected to multiple analysis of 
variance. The model expressions were found 
to be significant with an F value of 7.63, 
Probability value (P-value) 0.0108 as the 
probability value is less than 0.1 (upper limit). 
To understand the mathematical relationship 
between independent and dependent 
variables studied, a polynomial equation (Eq 
2) was generated using the Design Expert. 
 
% drug release (24 h) = 117.15 + 0.2973 * A 
+ 24.8262 * D …………….……………… (2) 
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The independent factors PEG 400 (A) and 
plasdone (D) had positive influence on drug 
release, while triacetin (B) and sorbitol (C) 
showed antagonistic effect on the response 
and, therefore, were excluded from the 
model. 
 
Influence of plasticizer on drug release 
 
In order to study the influence of plasticizer 
level on drug release profile, different types 
and levels of plasticizers were used. A 
polynomial model shows that increment in the 
plasticizer (PEG 400) led to an increase in 
drug release. Since PEG 400 is a hydrophilic 
plasticizer, it could be leached out easily and 
increase the flux rate of fluid. The more PEG 
400 incorporated into ethyl cellulose 
membrane, the lower the membrane 
permeability and drug release obtained due 
to the increased plasticity of the membrane. 
Another plasticizer, triacetin, is also a 
hydrophilic plasticizer but had negative 
influence on drug release; this could be due 
to its lower hydrophilicity compared to PEG 
400. 
 
Effect of level of pore former  
 
To study the effect of level of pore forming 
agent, core compositions were coated with 
coating compositions containing different 
types and levels of pore formers (Table 2). As 
the levels of pore formers (plasdone and 
sorbitol) increased from lower to higher level, 
the release also increased. The increase in 
theophylline release could be due to 
formation of more pores after coming in 
contact with aqueous environment. Drug 
release is higher with plasdone than with 
sorbitol owing to the greater aqueous 
solubility of the former.  
 
Influence of core formulation variables 
 
The response values of 1, 4, 8 and 24 h 
theophylline release were subjected to 
multiple analyses of variance using factorial 
model. For 1 h response, the model 
expressions were found to be significant with 
F (P - value) value of 0.7783 (0.0464). The 
polynomial equation for the factorial model is 
given by Eq 3. 
% drug release (1h) = 13.7475 + 0.9175 * A + 
1.505*E + 0.055 * F ………....…………… (3) 
For 4 h response, the model was found to be 
significant with F (P- value) of 4.1088 
(0.02073). The model is represented by Eq 4.  
% drug release (4h) = 47.9725 + 0.3875*B + 
2.7175 * C + 1.6475*E + 1.4525*F + 
0.9325*G   …………………………........... (4) 
The model for the response 8 h drug release 
was found to be consequential as the F (P - 
value) is 0.3509 (0.0185), and the model can 
be written as in Eq 5. 
% drug release (8 h) = 64.385 + 7.1525 * A + 
0.13 * B + 1.0125* D + 2.5525* 
E+1.135*F….............................................(5) 
At 24 h response, the model was found to be 
significant with F (P value) of 6.65 (0.049) as 
shown in Eq 6. 
% drug release (24h) = 80.8562+ 0.3687 * A 
+ 5.1362 * D + 3.4987* E ………………..(6) 
Where A = plasdone, B = crosscarmellose 
sodium, C = xanthan gum, D = potassium 
chloride (KCl), E = tartaric acid, F = sodium 
lauryl sulphate, and G = in process 
parameters. 
 
In all the four responses, factors with positive 
coefficients influence response 
synergistically, while factors with negative 
coefficients show antagonistic effect on the 
response. 
 
Influence of osmotic agents 
 
To study the compositive influence of osmotic 
agents (KCl and tartaric acid), drug delivery 
systems were developed with different 
concentrations of KCl and tartaric acid. From 
the polynomial equations obtained for all 
responses, it was confirmed that increase in 
the concentration of osmotic agent increases 
drug release as the positive coefficient value 
found for factors D and E is high and their 
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influence was seen in all the responses. 
When the coated tablet is exposed to an 
aqueous environment, water diffuses through 
the film coating (due to the active gradient of 
water), hydrating the core. The solvation of 
the osmotic agents creates osmotic pressure 
difference between the core contents and 
external environment results in greater 
theophylline release. 
 
Influence of swelling agents  
 
In the present study, swelling agents were 
used as drug entraining polymer, consisting 
of one or more swellable hydrophilic 
polymers (crosscarmellose sodium (factor B)  
and xanthan gum (factor C)) selected such 
that the polymeric swelling agent exhibits 
controlled swelling, the wall does not rupture 
or burst, and the desired rate of drug delivery 
can be obtained. However, swelling agents 
have less influence on all the responses (1, 
8, and 24h) except 4
th
 h which was endorsed 
by polynomial models.  
 
Influence of wetting agent 
 
Since theophylline is a poorly soluble drug, a 
micellar solubilizer, sodium lauryl sulphate 
(SLS), was used to enhance drug solubility 
for faster release. In addition, SLS (factor F) 
has been used as an osmotic agent to create 
osmotic pressure; this dual nature caused 
increase in drug release.  
 
In vitro release study 
 
Formulations F1+C3, F1+C11 and F1+C12 
showed 81.62 %, 75.85 % and 79.14 % drug 
release, respectively, as compared to other 
formulations, could be due to minimum level 
of plasticizer and maximum level of pore 
forming agent, but the release profile did not 
comply with USP limits for extended release 
capsules with 24 hour dosing interval 
21
  (see 
Table 4). In order to achieve USP release 
levels, responses (24 h release) from all the 
coating runs were included in the optimization 
design (i.e., Response surface reduced 
quadratic model) and the best solution for 
coating formulation was obtained. Optimized 
coating formula with F1 core formulation 
exhibited 94.12 % drug release which is near 
to the predicted value of 99.84 %, although it 





 h. The optimized coating was used to 
optimize tablet core runs of Taghuchi 
Orthogonal Array design. Formulations F1, 
F3, F8 showed 94.12%, 85.13% and 70.76% 
release respectively in relation to other 
formulations. The reason could be the 
elevated levels of osmotic agent (plasdone) 
which modifies crystalline nature of the drug, 
thus facilitating drug release, and the 
increased levels of solubilizing and swelling 
(crosscarmellose sodium) agents as they 
increase solubility and delivery rate, 
respectively; this is true for formulations F1 
and F8.   However, in the case of formulation 
F3, the sudden increase in drug release after 
8 h was due to ‘burst’ effect. Responses of all 
design runs were added in the optimization 
model. The results of optimization indicate 
the significant effect of osmotic agents (KCl 
and tartaric acid), plasdone and solubilizing 
agent on drug release. The ultimate 
optimized formulation showed 94.02 % with 
USP compliance in terms of release (see 
Table 4). 
 
Table 4: Comparison of release profile of 
USP theophylline extended release capsules 
(labeled for 24 h dosing) with optimized 

















1 5 - 15  15.98 
2 12 - 30  30.56 
4 25 – 50  52.04 
5 30 – 60  59.9 
8 55 - 75  75.88 
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Scanning electron microscopy 
 
Ethyl cellulose membranes obtained before 
and after dissolution, were studied by SEM. 
After the completion of dissolution, exhausted 
membrane contained plasticizer (PEG 400, 
38.10 %) and pore former (plasdone, 55.32 
%)  showed a microporous region surrounded 











Fig 1: Scanning electron microphotographs of 
coating membranes of optimized formulation 




Taguchi orthogonal design (for tablet core) 
and fraction factorial design (for coating) 
were adequately applied to study the effect of 
different formulation variables on the release 
profile to select optimized formulations. 
Membranes were found to develop 
pores/channels after coming in contact with 
aqueous environment; the number of pores 
being dependent on the initial level of the 
pore former in the membrane. Finally, it can 
be concluded that preparation of osmotic 
pump tablet can be simplified by coating the 
core tablet with a pore-forming agent which is 





1. Shokri J, Ahmadi P, Rashidi P, Shahsavari M, 
Rajabi-Siahboomi A, Nokhodchi A. Swellable 
elementary osmotic pump (SEOP): An 
effective device for delivery of poorly water-
soluble drugs. Eur J Pharm Biopharm, 2008; 
68: 289-297.  
2. Liu L, Che B. Preparation of monolithic osmotic 
pump system by coating the indented core 
tablet. Eur J Pharm Biopharm, 2006; 64: 180 -
84. 
3. Khan MA, Sastry SV, Vaithiyalingam SR, Agarwal 
V, Nazzal S, Reddy IK. Captopril 
gastrointestinal therapeutic system coated with 
cellulose acetate pseudo latex: evaluation of 
main effects of several formulation variables. 
Int J Pharm, 2000; 193: 147-156. 
4. Rose S, Nelson JF. A continous long-term injector. 
Aust J Exp Biol Med Sci, 1955; 33: 415-420. 
5. Theeuwes F, Swanson D, Wong P, Bonson P, 
Place V, Heimlich K, Kwan KC. Elementary 
osmotic pump for indomethacin. J Pharm Sci, 
1982; 72: 253-258. 
6. BittnerB, Thelly Th, Isel H, Mountfield RJ. The 
impact of co-solvents and the composition of 
experimental formulations on the pump rate of 
the ALZET osmotic pump. Int J Pharm, 2000; 
205: 195-198. 
7. Higuchi T, Leeper HM. Osmotic dispenser with 
means for dispensing active agent responsive 
to osmotic gradient, 1976; US Patent No. 
3,995, 631.  
8. Prabakaran D, Singh P, Kanaujia P, Jaganathan 
KS, Rawat A, Vyas SP. Modified push-pull 
osmotic system for simultaneous delivery of 
theophylline and salbutamol: development and 
in vitro characterization. Int J Pharm, 2004; 
284: 95-108. 
9. Thombre AG, Appel LE, Chidlaw MB, Daugherity 
PD, Dumont F, Evans LAF, Sutton SC. 
Osmotic drug delivery using swellable-core 
technology. J Cont Rel, 2004; 94: 75-89. 
10.  Garg A, Gupta M, Bhargava HN. Effect of 
formulation parameters on the release 
characteristics of propranolol from asymmetric 
membrane coated tablets. Eur J Pharm 
Biopharm, 2007; 67: 725–731. 
11. Mullett WM, Lai EPC. Rapid determination of 
theophylline in serum by selective extraction 
using a heated molecularly imprinted polymer 
micro-column with differential pulsed elution. J 
Pharm Biomed Anal, 1999; 21: 835-843. 
12. Barnes PJ. Theophylline: New Perspectives for an 
Old Drug. Am J Respir Crit Care Med, 2003; 
167: 813-818. 
13. Zhang KE, Huang H, Wu X, Cai R, Korenaga T. 
Stopped-flow kinetic study on intermediate of 
theophylline oxidation reaction via rapid-
scanning uv/vis spectroscopy. Anal Sci, 1997; 
13: 475-478. 
14. Hansch C, Sammes PG, Taylor JB. Comprehensive 
medicinal chemistry. Oxford, England, 
Pergamon Press, Vol. 6, 2005, pp 895.  
15. Ansari M, Kazemipour M,  Shahriar M. 
Simultaneous quantitation of theophylline and 
guaifenesin in syrup by HPLC, derivative and 
derivative ratio spectrophotometry for quality 
control purpose. Iranian J Pharmacol Ther, 
2006; 5: 67-72. 
16. Tripathi KD. Essentials of medical pharmacology. 
New Delhi, Jaypee brothers medical 
Publishers, 6
th
 edition, 2008, pp 220. 
A B 
Rao  et al  
Trop J Pharm Res, June 2009; 8 (3):  255 
17.  Barnes PJ, Pauwels. Theophylline in the 
management of asthma: time for reappraisal? 
Eur Respir J, 1994; 7: 579 – 591. 
18. Singh B, Kumar R, Ahuja N. Optimizing drug 
delivery system using systematic “design of 
experiments” part I fundamental aspects. 
Critical reviews in therapeutic drug carrier 
systems.2004; 22: 27-105. 
19.  Huang YT, Tsai TR, Cheng CJ, Cham TM, Lai TF, 
ChuoWH.
 
Formulation Design of a Highly 
Hygroscopic Drug (Pyridostigmine Bromide) 
for its Hygroscopic Character Improvement 
and Investigation of In Vitro/In Vivo Dissolution 
Properties Drug Dev and Ind Pharm, 2007; 33: 
403 – 416 
20. Loukas YL. Fractional factorial design via fold over: 
application to optimization of novel 
multicomponent vesicular systems. Analyst, 
1997; 122: 1023-7.  
21. US Pharmacopoeia and National Formulary, ed 24, 
United Pharmacopeial Convention, 
Inc.,Rockville, 2000. 1630-1. 
 
